Skip to main content
. 2018 Feb 15;14:1744806918762205. doi: 10.1177/1744806918762205

Table 5.

Surface under the cumulative ranking curve (SUCRA) values for different treatments for all outcomes in psoriasis patients.

Outcomes PBO AM ANT Anti-IL12/23 Anti-IL17 Anti-TNF-α
PASI 50 0.171 0.421 0.520 0.997 0.571 0.819
PASI 75 0.167 0.341 0.493 0.854 0.980 0.666
PASI 90 0.168 0.356 0.518 0.829 0.995 0.632
DLQI 0.342 0.495 0.506 0.842 0.617 0.699
PGA 0.171 0.465 0.368 0.823 0.998 0.676
AAE 0.782 0.474 0.904 0.580 0.281 0.480
Infection 0.910 0.761 0.643 0.427 0.352 0.407
Nasopharyngitis 0.874 0.643 0.588 0.454 0.517 0.423
Headache 0.972 0.501 0.495 0.554 0.363 0.615
URTI 0.861 0.171 0.745 0.602 0.415 0.706
Withdrawal 0.359 0.179 0.702 0.800 0.669 0.791

PASI 50: ≥50% reduction in psoriasis area and severity index; PASI 75: ≥75% reduction in psoriasis area and severity index; PASI 90: ≥90% reduction in psoriasis area and severity index; DLQI: Dermatology Life Quality Index; PGA: Physician’s Global Assessment – minimal or cleared; AAE: all adverse events; URTI: upper respiratory tract infection; AM: anti-metabolites; anti-TNF-α: anti-tumor necrosis factor-α agents; ANT: anti-T-cell agents; anti-IL12/23: anti-interleukin-12/23 agents; anti-IL17: anti-interleukin-17 agents; PBO: placebo.